Agilent Technologies appoints new Chief Technology Officer

Published 28/05/2025, 13:38
Agilent Technologies appoints new Chief Technology Officer

SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE: A), a global provider of analytical and clinical laboratory technologies with a market capitalization of $31.7 billion, announced the appointment of August Specht, Ph.D., as its new Chief Technology Officer. Specht, who has over 25 years of experience in the industry, will assume his new role on Thursday, June 9. According to InvestingPro analysis, Agilent maintains a GOOD financial health score, suggesting strong operational stability.

Specht’s extensive background includes a tenure as vice president of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific. He has also held various leadership positions in R&D, product management, strategy, and business development at Thermo Fisher and Varian Instruments.

Padraig McDonnell, President and CEO of Agilent, expressed enthusiasm for Specht’s appointment, citing his deep understanding of the scientific community’s needs and his track record of delivering innovative solutions.

August Specht earned his Bachelor of Science (Honors) in Chemistry from Queen’s University in Canada, a Ph.D. in Analytical Chemistry from the University of British Columbia, and an MBA from the University of California, Berkeley.

Agilent is known for its comprehensive range of solutions, including instruments, software, services, and expertise that support scientific research and innovation. The company, which generated $6.51 billion in revenue in the fiscal year 2024, employs approximately 18,000 people across the globe.

This announcement is based on a press release statement from Agilent Technologies Inc.

In other recent news, Agilent Technologies Inc. reported revenue of $6.51 billion for the fiscal year 2024, showcasing its role as a leader in analytical and clinical laboratory technologies. Agilent announced the appointment of Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown to its Board of Directors, marking a strategic enhancement as the company embarks on its "Ignite Transformation" initiative. Meanwhile, Jefferies maintained a Hold rating on Agilent but lowered its price target from $135 to $116, citing conservative market conditions despite the company’s strong order demand in its CDMO business. New Found Gold Corp. has commenced its 2025 work program at the Queensway Gold Project, focusing on drilling, geological mapping, and sampling to expand gold resources. The company is also participating in several North American conferences to engage with potential investors and industry stakeholders. Additionally, New Found Gold has issued new stock options, aiming to incentivize and retain key employees. These developments reflect ongoing efforts by both companies to enhance their strategic positions and maintain transparency with investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.